WhiteSwell Medical

Acute Decompensated Heart Failure Treatment

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in September 2014, WhiteSwell Medical operates with 11–50 employees. The company has raised $30 million across one funding round from two investors. In December 2018, WhiteSwell Medical secured $30 million in funding.

Business overview

WhiteSwell Medical is a science-driven company focused on improving the treatment of acute decompensated heart failure (ADHF), a major cause of repeat hospitalizations. The company is developing a minimally invasive, catheter-based approach designed to enhance the natural fluid-removal process of the lymphatic system, thereby more efficiently removing excess interstitial fluid in ADHF patients. It operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In January 2022, WhiteSwell Medical expanded its senior management team with experienced executives. This move signals a strategic strengthening of leadership, likely in preparation for further development, clinical trials, or market entry for its catheter-based ADHF treatment. For investors, this indicates a company building out its operational capabilities and expertise to advance its innovative medical device.

Log in to access full profile

Company Intelligence Q&A

What is WhiteSwell Medical's primary focus?
WhiteSwell Medical is dedicated to improving the treatment of acute decompensated heart failure (ADHF), a significant cause of repeat hospitalizations and emergency room visits.
What is the core technology WhiteSwell Medical is developing?
WhiteSwell Medical is developing a minimally invasive, catheter-based approach designed to more efficiently remove excess interstitial fluid in patients with ADHF by enhancing the natural fluid-removal process of the lymphatic system.
When did WhiteSwell Medical strengthen its patent portfolio?
In December 2020, WhiteSwell Medical strengthened its patent portfolio for the treatment of acute decompensated heart failure with a newly issued U.S. patent.
Has WhiteSwell Medical made recent changes to its leadership?
In January 2022, WhiteSwell Medical added experienced executives to its senior management team, enhancing its leadership and operational capabilities.
How much capital has WhiteSwell Medical raised?
WhiteSwell Medical has raised $30 million across one funding round. This round was joined by RA Capital Management and InCube Ventures in December 2018.
Log in to access full profile